D
Neuphoria Therapeutics Inc. NEUP
$4.40 $0.184.27% NASDAQ
Recommendation
Prev Close
$4.55
Volume
475,127
Avg Vol (90D)
1,091,941
Market Cap
$10.73M
Dividend & Yield
--
52-Week Range
$2.90 - $21.40
P/E (TTM)
7.07
EPS (TTM)
$0.64
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Does This Valuation Of Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Imply Investors Are Overpaying?
11/5/2025 - Simply Wall St
Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of ...
10/27/2025 - GuruFocus
Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process
10/27/2025 - Globe Newswire
Best Biotech Stocks To Research - October 26th
10/27/2025 - MarketBeat
Best Biotech Stocks To Keep An Eye On - October 25th
10/26/2025 - MarketBeat
Insiders Are Scooping Up Shares of a Miner, a Driller, and a Biotech
10/25/2025 - 24/7 Wall St.
Ford, Intel, AMD, Neuphoria Therapeutics, Deckers Outdoor: Stocks Making The Biggest Moves Today
10/24/2025 - Stocktwits News Feed
Lynx1 Capital Management Lp Acquires 639,110 Shares of Neuphoria Therapeutics (NASDAQ:NEUP) Stock
10/24/2025 - MarketBeat
neuphoria nixes social anxiety program and starts strategic review after ph 3 flop
10/21/2025 - FierceBiotech.com - Biotech
Neuphoria Therapeutics just downgraded at Lucid Capital, here's why
10/21/2025 - The Fly
Neuphoria Therapeutics (NEUP) Discontinues SAD Program After Trial Results
10/20/2025 - GuruFocus
Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the ...
10/20/2025 - GuruFocus
Neuphoria Therapeutics Inc trading resumes
10/20/2025 - TipRanks Financial Blog
Neuphoria Therapeutics Inc trading resumes
10/20/2025 - The Fly
Neuphoria AFFIRM-1 trial misses primary endpoint, to discontinue SAD program
10/20/2025 - TipRanks Financial Blog
Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder
10/20/2025 - Globe Newswire
Neuphoria Therapeutics Inc trading halted, news pending
10/20/2025 - TipRanks Financial Blog
Neuphoria Therapeutics Inc trading halted, news pending
10/20/2025 - The Fly
Neuphoria Therapeutics (NASDAQ:NEUP) Releases Earnings Results, Misses Estimates By $4.53 EPS
9/30/2025 - Ticker Report
Neuphoria Therapeutics Inc. Full Year Loss Drops
9/30/2025 - Nasdaq News: Markets
Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates
9/29/2025 - Globe Newswire
Neuphoria Therapeutics price target raised to $35 from $18 at Maxim
9/11/2025 - TipRanks Financial Blog
Neuphoria Therapeutics price target raised by $17 at Maxim, here's why
9/11/2025 - The Fly
Maxim Group Sticks to Their Buy Rating for Neuphoria Therapeutics (NEUP)
9/10/2025 - TipRanks Financial Blog
Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in ...
9/4/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
$15.65M
EBITDA (TTM)
-$166.30K
EBIT (TTM)
-$829.10K
Net Income (TTM)
-$369.60K
Balance Sheet
Total Assets (Q)
$28.59M
Total Debt (Q)
$149.10K
Total Liabilities (Q)
$9.59M
Book Value Per Share (Q)
$9.60
Cash Flow
Cash from Operations (TTM)
$77.20K
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$1.53M
Net Change in Cash (TTM)
$1.60M
Filings
Filing Date
Monday, September 29, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 10 and 14 (est)
Price History
Loading...
Beta
--
7-Day Total Return
8.64%
30-Day Total Return
-55.38%
60-Day Total Return
-40.78%
90-Day Total Return
-35.29%
Year to Date Total Return
50.17%
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Jan 02, 2025 - $2.90
52-week High
Oct 07, 2025 - $21.40
Valuation
Market Cap
$10.73M - Nano Cap
Enterprise Value
-$3.33M
Price/Sales (TTM)
0.55
Price/Book (Q)
0.47
Dividends and Shares
Shares Outstanding
1.90
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.neuphoriatx.com
Phone Number
781 439 5551
Address
100 Summit Drive
Burlington, MA 01803
Country
United States
Year Founded
1996
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in... more
NASDAQ 11/05/2025 4:00PM Eastern Quotes delayed